Ariad Pharmaceuticals


Insider Selling News: QUALCOMM, Inc. (QCOM), Pandora Media Inc (P), Ariad Pharmaceuticals (ARIA), Intercept Pharmaceuticals Inc (ICPT)

Recently, various executives have taken part in insider selling activity for the stocks of QUALCOMM, Inc. (NASDAQ:QCOM), Pandora Media Inc (NYSE:P), Ariad Pharmaceuticals, …

Company Update (NASDAQ:ARIA): Ariad Pharmaceuticals, Inc. Announces Dismissal of Shareholder Class Action Lawsuit in Federal District Court

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late …

H.C. Wainwright Boosts Price Target For Ariad Pharmaceuticals On The Back Of 4Q14 Iclusig Sales

In a research report released on Monday, H.C.

Cowen Believes Ariad Pharmaceuticals Stock Is Fairly Valued

Cowen’s healthcare analyst Phil Nadeau came out with a research note on Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), following the company’s earnings release for the fourth-quarter.

ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2014 Financial Results

(BUSINESS WIRE)–Jan. 29, 2015– ARIAD Pharmaceuticals, Inc.

ARIAD Announces Appointment of Thomas J. DesRosier, Senior Pharmaceutical-Industry Counsel, as Chief Legal and Administrative Officer

(BUSINESS WIRE)–Jan. 22, 2015– ARIAD Pharmaceuticals, Inc.

ARIA: ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years

Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts